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Abstract
Background: Candida prosthetic endocarditis (CPE) is an uncommon disease involving less than 1 % of infective
endocarditis patients and associated with high recurrence rate. Immunosuppresion, intravenous drug abuse, cardiac
surgery and indwelling foreign bodies are the major risk factors for CPE. There are very few reported cases of CPE
where more than one surgery was performed and there has generally been limited follow up on these cases.
Case presentation: We report a case of a 35 year old woman who had mitral valve annuloplasty complicated by
recurrent episodes of CPE leading to multiple mitral valve replacements (MVR). She underwent MVR surgeries a
total of four times over an eighteen year period and had good functionality during most of this time while being
on antifungal suppressive treatment. This is a unique case in terms of numbers of surgeries performed, the length
of the follow up and the involvement of three different Candida species.
Conclusion: Current guidelines for the treatment of candida endocarditis recommend surgical treatment followed
by long term antifungal therapy although the cure rate by all treatments is low. However we feel that based on
this one case it is reasonable to consider multiple redo valve replacement surgeries in conjunction with antifungal
treatment for selected patients stable enough to tolerate the surgery.
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Background
Candida prosthetic endocarditis (CPE) is an uncommon
disease involving less than 1 % of infective endocarditis
cases and up to 3.4 % of prosthetic valve infections. CPE
has an incidence of less than 1 case per year even at
tertiary care centers which is increasing secondary to
intravenous drug abuse [1–4]. CPE is associated with a
low cure rate with recurrence of up to 36 % and has 5-
year survival of less than 50 % [1, 2, 4]. The high risk
populations are those who are immunocompromised,
intravenous drug abuser, previous cardiac surgery and
those with indwelling foreign bodies such as catheters,
pacemakers, or prosthetic joints [2, 5–10]. CPE usually
leads to an acute and progressive valvular dysfunction
causing multiple complications such as heart failure,
embolic phenomena and stroke [1, 2, 11]. One possible
explanation is the lack of blood supply to the prosthesis
and surrounding tissue and subsequent impaired im-
mune response. Furthermore candida can form a bio-
film on the prosthesis surface which is resistant to
treatment and thus may require lifelong suppressive
therapy [2, 12]. Current guidelines recommend surgical
treatment followed by long term antifungal therapy al-
though the cure rate by all modality of treatments is
low [13, 14]. Apparent long term cure have occurred by
both medical and surgical therapy [2, 10, 13, 14].
Case presentation
We report a case of a 35 year old female who had mitral
valve (MV) commissurotomy and ring annuloplasty
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(32 mm Carperntier) on July 28, 1987 for rheumatic
valvular disease. Fifteen months after this surgery, she
presented with an embolic event to posterior cerebellar
artery. Her blood cultures were positive for Candida tro-
picalis. Echocardiography showed moderate mitral sten-
osis with 0.5 × 0.4 cm density on the anterior portion of
the ring behind the mitral valve consistent with fungal
vegetation. She did not improve clinically after treatment
with amphotericin B and required a 31 mm Medtronic
Hall mechanical prosthesis on 10/17/88 which was
followed by chronic outpatient suppressive treatment
with fluconazole.
In August 1989, she presented to the hospital with
pancytopenia, splenomegaly and renal failure. A large
fungal vegetation was noted on the MV annulus and
blood cultures were positive for a different species of
candida (C. parapsilosis) leading to her third mitral valve
procedure (second replacement) on 8/14/1989. She was
discharged home and enjoyed a period of seven years
with good functionality while being on 200 mg per day
of fluconazole suppressive therapy.
In December 1996, she presented with three weeks of
fever, marked splenomegaly and hemorrhagic infarct of
the left optic disc. Her blood cultures grew C. parapsilo-
sis prompting the initiation of amphotericin B and flu-
conazole therapy and surgical consultation at University
of Virginia (UVa) for the third episode of CPE. The
fourth mitral valve procedure (third replacement) was
performed on 1/22/1997 at UVa followed by increased
dose of fluconazole (400 mg per day).
In November 1998, she presented with continued fever,
heart failure and overt pulmonary edema secondary to C.
tropicalis prosthetic MV endocarditis with positive blood
cultures. TEE showed dilated and hypokinetic right
ventricle, severe tricuspid and mitral valve regurgitation
with an LV ejection fraction of 35 %, and severely ele-
vated pulmonary artery pressure (80–90 mmHg). The
fifth, and last, mitral valve procedure [fourth replace-
ment (St Jude Valve)] was performed on 11/23/1998 at
UVa due to worsening heart failure and pulmonary
edema. Due to recurrent CPE, she was also considered
for heart transplant but repeat MVR along with on-
going antifungal treatment was thought to be better.
She was discharged on liposomal amphotericin B three
times a week to correspond with her visits for erythro-
poietin infusion secondary to pancytopenia before re-
suming fluconazole. She was closely followed on oral
fluconazole at 800 mg daily from January 1999 until
2006. She consistently denied using any intravenous
drug or medication noncompliance. During this 7 year
period, she enjoyed an active lifestyle including camping
and fishing.
Worsening pancytopenia and splenomegaly developed
in the second half of 2006 secondary to recurrent C.
parapsilosis MV vegetation with positive blood cultures
which led to biventricular heart failure, multiorgan fail-
ure, pancytopenia and acute kidney injury requiring
hemodialysis. The candida species was still sensitive to
fluconazole, voriconazole, itraconazole, amphotericin
B and 5-flucytosine. The patient was felt not to be a
candidate for redo surgery and subsequently died in
November 2006.
Discussion
Our patient enjoyed a good quality of life for more than
18 years following her first valve surgery for CPE and
16 years following her first of multiple valve replace-
ments for CPE. Moreover, she survived 8 years following
her last of four mitral valve replacement surgeries on
fluconazole suppressive therapy.
We were able to find only three other similar cases in
the literature who had more than one surgery performed
for CPE [1, 15, 16]. The first patient developed CPE
three years after the valve replacement but had discon-
tinued the suppressive antifungal therapy for 8 months
before the recurrence [1]. Another patient was treated
with caspofungin after aortic valve replacement (AVR)
for CPE but developed recurrence two months later and
required a second AVR with a cryopreserved homograft.
The patient was then managed medically with liposomal
amphotericin B followed by fluconazole [15]. The third
patient was treated with amphotericin B for C. parapsi-
losis aortic valve CPE but developed recurrence after
4.5 months and died during reoperation [16]. The lon-
gest reported survival noted was for our patient who had
two different types of candida species.
The common candida species causing endocarditis are
C. albicans followed by C. parapsilosis [17]. The later organ-
ism now exceeds C. albicans in terms of frequency. Our pa-
tient, felt to be a non intravenous drug user, is unique in
having two different candida organisms. API 20C [18] and
Chromogenic medium [19] were used for isolation and ap-
propriate identification of the candida species. Since these
techniques are highly sensitive in identifying the type of can-
dida species and it is very rare to have growth of different
candida species during subsequent recurrences which makes
us suspicious if the candida species was very slow growing
and not detected during the microbiologic culture.
Infectious Diseases Society of America (IDSA) and
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines for treatment of native and
prosthetic valve endocarditis recommend valve replace-
ment along with antifungal treatment with amphotericin
B with or without 5-flucytosine followed by long-term
suppressive therapy with fluconazole [13, 14]. Immediate
surgery has been assigned grade A recommendation by
ESCMID and grade B by IDSA but both are level III evi-
dence derived from opinions of respected authorities,
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based on clinical experience, descriptive case studies or
expert committees. For those who are unable to undergo
surgical removal of the valve, chronic lifelong suppression
with fluconazole 400–800 mg (6–12 mg/kg) daily for life-
long is recommended [14]. Echinocandins may be more
effective for candida species producing biofilms since a
trend towards better outcome in patients receiving caspo-
fungin at diagnosis has been reported [9].
Despite the guidelines, there is still a therapeutic di-
lemma regarding proper treatment of all types of fungal
endocarditis (FE) due to the lack of controlled studies
comparing the combination of antifungal and surgical
therapy versus surgery or medical therapy alone. We can
categorize the treatment options for fungal prosthetic
endocarditis as a) antifungal monotherapy, b) combin-
ation antifungal therapy, c) surgery alone, d) surgery and
antifungal, and e) surgery and combination antifungal
therapy.
In a meta-analysis of surgical versus medical treatment
for both prosthetic and non-prosthetic candida endocardi-
tis, antifungal monotherapy was associated with the poorer
patient outcomes compared to combination antifungal
agents [20]. This observation led to the suggestion that
combination antifungal therapy may be better than mono-
therapy for nonsurgical patients [20].
It is obviously difficult to compare clinical outcomes of
medical treatment versus the combination of medications
and surgery due to different baseline comorbidities and
demographics. Antifungal monotherapy or sequential
therapy combined with surgical approach has been used
variably by different institutions [1–3, 5]. Both patients
with FE and CPE tend to have high mortality rate when
treated with single or multiple antifungal agents compared
to those treated with combination of surgery and antifun-
gal agents [1, 4, 10, 20, 21]. Thus current guidelines advise
combined medical and surgical treatment for FE who are
deemed suitable for surgery [13, 14].
However, the overall relapse which usually happens
after stopping oral antifungal suppressive therapy in all
types of FE can reach more than 40 % [1, 10, 21–23].
Valve tissues have been found to be positive for candida
for more than two decades leading to CPE [2, 5, 24].
There is no clear recommendation in the current guide-
lines regarding the duration of antifungal treatment after
the valve surgery but there is a trend to continue anti-
fungal suppressive treatment for lifelong.
Conclusions
Our patient with recurrent candida prosthetic endocarditis
had a total of four valve replacement surgeries following
the initial mitral annuloplasty with prolonged periods of
good functionality between the surgeries. It is reasonable
to argue that the recurrent surgeries along with lifelong
suppressive antifungal therapy helped our patient enjoy a
good quality of life with minimum hospitalization in com-
parison to her life on medical therapy alone.
There are not enough cases or evidence reported to
establish standard guidelines for treating CPE. The
current recommendations advise a combined medical
and surgical approach. However we feel that based on
this case it is reasonable to consider multiple redo valve
replacement surgeries in conjunction with antifungal
treatment as an option for selected patients stable
enough to tolerate the surgery.
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